Conduit Pharmaceuticals strengthens its Board of Directors with the addition of Simon Fry, a seasoned investment banking executive with over 30 years of experience in asset management, capital markets, and strategy development. NAPLES, Fla. and CAMBRIDGE, United Kingdom, Nov. 19, 2024 (GLOBE NEWSWIRE) -- Conduit Pharmaceuticals Inc. (Nasdaq: CDT) (“Conduit” or the “Company”), a multi-asset, clinical stage, disease-agnostic... Read More

Conduit Pharmaceuticals announces new addition to its autoimmune pipeline, underscored by composition of matter patent filing to strengthen its competitive position This new asset, CDT1656, combines AZD1656 with a second known-compound that has demonstrated immune-modulating effects across multiple autoimmune conditions, enhancing its therapeutic potential The addition of CDT1656 and the supporting composition of matter... Read More

SAN DIEGO and LONDON, Nov. 01, 2024 (GLOBE NEWSWIRE) -- Conduit Pharmaceuticals Inc. (Nasdaq: CDT) (“Conduit” or the “Company”), today announced the restructuring of a portion of its financial obligations, enhancing its balance sheet and liquidity. The Company has restructured the $2.65 million loan note with Nirland Limited (“Nirland”) and secured $1.2 million in new promissory notes through separate agreements with third... Read More

SAN DIEGO and LONDON, Aug. 28, 2024 (GLOBE NEWSWIRE) -- Conduit Pharmaceuticals Inc. (Nasdaq: CDT) (“Conduit” or the “Company”), today announced it will be participating in the H.C. Wainwright 26 th Annual Global Investment Conference, being held September 9-11, 2024. Dr. David Tapolczay, Founder and CEO of Conduit, will give a virtual presentation available on-demand starting on September 9 th at 7:00 am ET/12:00 pm BST.... Read More

Conduit Pharmaceuticals announces plans to initiate Phase 2a trials in both systemic lupus erythematosus and ANCA-associated vasculitis for its lead clinical candidate, AZD1656 AZD1656, a HK-4 glucokinase activator initially developed by AstraZeneca for diabetes, is now being repurposed by Conduit for autoimmune disorders, leveraging its established safety profile and targeted immune-modulating effects SAN DIEGO and LONDON,... Read More

Conduit Pharmaceuticals enters into exclusive license agreement with AstraZeneca for HK-4 Glucokinase activators AZD1656 and AZD5658 targeting autoimmune indications and myeloperoxidase inhibitor AZD5904 targeting idiopathic male infertility Assets have shown favorable preclinical and Phase I data. Conduit to initiate Phase II clinical trials SAN DIEGO and LONDON, Aug. 08, 2024 (GLOBE NEWSWIRE) -- Conduit Pharmaceuticals... Read More

SAN DIEGO and LONDON, July 16, 2024 (GLOBE NEWSWIRE) -- Conduit Pharmaceuticals Inc. (Nasdaq: CDT) ("Conduit Pharmaceuticals" or "Conduit" or the “Company”) today announced the approval of a composition of matter patent application by IP Australia, achieving successful examination of a patent on its lead asset, an HK-4 Glucokinase Activator which targets a wide range of autoimmune diseases. The Company is enrolled to... Read More

SAN DIEGO and LONDON, June 13, 2024 (GLOBE NEWSWIRE) -- Conduit Pharmaceuticals Inc. (Nasdaq: CDT) (the “Company” or “Conduit"), today announced the Company is set to join the broad-market Russell 3000® Index at the conclusion of the 2024 Russell US Indexes annual reconstitution, effective at the open of US equity markets on Monday, July 1, 2024, according to a preliminary list of additions posted by FTSE Russell on Friday,... Read More

Conduit also appoints prominent intellectual property attorney Jeffrey Lindeman as a Consultant Leadership additions underscore Conduit’s commitment to strengthening and broadening its intellectual property portfolio through solid-form technology to maximize future value SAN DIEGO and LONDON, March 19, 2024 (GLOBE NEWSWIRE) -- Conduit Pharmaceuticals Inc. (Nasdaq: CDT) ("Conduit Pharmaceuticals" or "Conduit" or the... Read More

SAN DIEGO and LONDON, March 11, 2024 (GLOBE NEWSWIRE) -- Conduit Pharmaceuticals Inc. (Nasdaq: CDT) ("Conduit Pharmaceuticals" or "Conduit") today announced the opening of cutting-edge laboratory space in Cambridge, United Kingdom, a global centre for research and development for companies at the forefront of life science innovation. This strategic acquisition marks a pivotal milestone for Conduit, positioning the Company... Read More

SAN DIEGO and LONDON, Jan. 31, 2024 (GLOBE NEWSWIRE) -- Conduit Pharmaceuticals Inc. (Nasdaq: CDT) ("Conduit"), a multi-asset, clinical-stage life science company delivering an efficient model for compound development, today announced CEO Dr. David Tapolczay, will be participating in the Oppenheimer 34th Annual Healthcare Life Sciences Conference, being held February 13-14, 2024. Dr. Tapolczay is scheduled to present on... Read More

SAN DIEGO and LONDON, Nov. 02, 2023 (GLOBE NEWSWIRE) -- Conduit Pharmaceuticals Inc. (Nasdaq: CDT) (“Conduit Pharmaceuticals” or “Conduit”), a multi-asset clinical-stage disease-agnostic life science company delivering an efficient model for compound development, today announced that its CEO, Dr. David Tapolczay, and its CFO, Adam Sragovicz, will be attending the 14th Annual Jefferies London Healthcare Conference, taking... Read More